<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01634269</url>
  </required_header>
  <id_info>
    <org_study_id>MDT-2111 23 mm trial</org_study_id>
    <nct_id>NCT01634269</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of MDT-2111 in Subjects With Small Aortic Annuli and Symptomatic Severe Aortic Stenosis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiovascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the present trial is to demonstrate the effectiveness of the
      MDT-2111 in the treatment of symptomatic severe aortic stenosis in subjects with small aortic
      annuli and deemed difficult for surgical operation.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in composite score of New York Heart Association (NYHA) Class and effective orifice area (EOA).</measure>
    <time_frame>baseline and 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in NYHA classification from baseline</measure>
    <time_frame>baseline and 30 days, 6 months, 12 months, and annually thereafter up to five years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The occurrence of individual Major Adverse Cardiovascular and Cerebrovascular Event (MACCE) components</measure>
    <time_frame>5 Years</time_frame>
    <description>MACCE is defined as a composite of:
all-cause death
myocardial infarction (MI)
all stroke, and
reintervention (defined as any cardiac surgery or percutaneous reintervention catheter procedure that repairs, otherwise alters or adjusts, or replaces a previously implanted valve)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success as defined in the description.</measure>
    <time_frame>from admission for procedure to discharge, on average less than 1 week</time_frame>
    <description>successful vascular access, delivery and deployment of the device, and successful retrieval of the delivery system
correct position of the device in the proper anatomical location (placement in the annulus with no impedance on device function)
Intended performance of the prosthetic valve (aortic valve area &gt;1.2 cm2 (by echocardiography using the continuity equation) and mean aortic valve gradient &lt; 20 mmHg or peak velocity &lt; 3 m/sec, without moderate or severe prosthetic valve AR)
Only one valve implanted in the proper anatomical location</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural success, defined as device success and absence of in-hospital MACCE</measure>
    <time_frame>from admission for procedure to discharge, on average less than 1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic assessment of prosthetic valve performance</measure>
    <time_frame>5 Years</time_frame>
    <description>Measured by transvalvular mean gradient, effective orifice area, degree of aortic valve regurgitation (transvalvular and paravalvular), left ventricular ejection fraction (LVEF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repeat hospitalization</measure>
    <time_frame>5 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Valve-related deaths</measure>
    <time_frame>5 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All adverse events</measure>
    <time_frame>5 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life assessment using SF-36 questionnaire</measure>
    <time_frame>5 Years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>MDT-2111 TAVI 23 mm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MDT-2111 TAVI 23 mm</intervention_name>
    <description>Device: 23 mm MDT-2111 System for Transcatheter Aortic Valve Implantation (TAVI) Transcatheter Aortic Valve Implantation (TAVI) using the 23 mm MDT-2111 system.</description>
    <arm_group_label>MDT-2111 TAVI 23 mm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must have co-morbidities such that one cardiologist and one cardiac surgeons
             agree that medical factors preclude operation, based on a conclusion that the
             probability of death or serious morbidity exceeds the probability of meaningful
             improvement.

          2. Subject has senile degenerative aortic valve stenosis with:

             mean gradient &gt; 40 mmHg or jet velocity greater than 4.0 m/s by either resting or
             dobutamine stress echocardiogram, or simultaneous pressure recordings at cardiac
             catheterization (either resting or dobutamine stress), AND an initial aortic valve
             area of ≤ 0.8 cm2 (or aortic valve area index ≤ 0.5 cm2/m2) by resting echocardiogram.

          3. Subject is symptomatic from his/her aortic valve stenosis, as demonstrated by NYHA
             Functional Class Class III or greater. If screening committee agrees the eligibility
             of a patient with class II , based on medical factors, he/she can be enrolled.

          4. Patient has been informed of the nature of the trial and has signed an Informed
             Consent Form.

          5. Patient agrees to comply with specified follow-up evaluations and to return to the
             same investigational site where the procedure was performed.

        Exclusion Criteria:

          1. Evidence of an acute myocardial infarction ≤ 30 days prior to the intended treatment.

          2. Any percutaneous coronary or peripheral interventional procedure performed within 30
             days prior to the procedure.

          3. Blood dyscrasias as defined:

               -  Leukopenia (WBC count &lt; 1,000 cells/mm3)

               -  Thrombocytopenia (platelet count &lt;50,000 cells/mm3)

               -  History of bleeding diathesis or coagulopathy

               -  Hypercoagulable states

          4. Untreated clinically significant coronary artery disease requiring revascularization.

          5. Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or
             mechanical hemodynamic support.

          6. Need for emergency surgery for any reason.

          7. Severe ventricular dysfunction with left ventricular ejection fraction (LVEF) &lt; 20% as
             measured by resting echocardiogram.

          8. Recent (within 6 months) cerebrovascular accident (CVA) or transient ischemic
             attack(TIA).

          9. End stage renal disease requiring chronic dialysis.

         10. GI bleeding within the past 3 months.

         11. A known hypersensitivity or contraindication to any of the following which cannot be
             adequately pre-medicated:

               -  Aspirin

               -  Ticlopidine

               -  Heparin

               -  Contrast media

               -  Nitinol (titanium and nickel alloy)

         12. Ongoing sepsis, including active endocarditis.

         13. Subject refuses a blood transfusion.

         14. Life expectancy &lt; 12 months due to associated non-cardiac co-morbid conditions.

         15. Other medical, social, or psychological conditions that in the opinion of an
             Investigator precludes the subject from appropriate consent.

         16. Severe dementia (resulting in either inability to provide informed consent for the
             trial/procedure, prevents independent lifestyle outside of a chronic care facility, or
             will fundamentally complicate rehabilitation from the procedure or compliance with
             follow-up visits).

         17. Currently participating in an investigational drug or another device trial. Note:
             Trials requiring extended follow-up for products that were investigational, but have
             since become commercially available, are not considered investigational trials.

         18. Symptomatic carotid or vertebral artery disease.

         19. Native aortic annulus size &lt; 18 mm or &gt; 20 mm per the screening diagnostic imaging.

         20. Pre-existing prosthetic heart valve in any position.

         21. Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant
             aortic regurgitation).

         22. Mitral regurgitation (moderate to severe) or severe tricuspid regurgitation.

         23. Moderate to severe mitral stenosis.

         24. Hypertrophic obstructive cardiomyopathy.

         25. Echocardiographic evidence of intracardiac mass, thrombus or vegetation.

         26. Severe basal septal hypertrophy with an outflow gradient.

         27. Ascending aorta diameter &gt; 34 mm

         28. Congenital bicuspid or unicuspid valve verified by echocardiography.

         29. For patients with native coronary artery dependent circulation:

               -  Sinus of valsalva width &lt; 25 mm OR

               -  Height of the left or right coronary sinus of valsalva (to the tubular aorta) &lt;
                  15mm.

         30. Femoral or iliac artery of the first choice corresponding to any one of the
             followings:

               -  Angle at aortic root (the angle between aortic valve annulus plane and horizontal
                  plane/vertebra) exceeds 70°.

               -  Vessel diameter of femoral or iliac artery is less than 6 mm.

               -  Aorta has severe calcification, excess tortuosity or severe atherosclerosis.

               -  Transarterial access not able to accommodate an 18Fr sheath.

         31. Subclavian artery of the second choice corresponding to any one of the followings:

               -  Angle at aortic root (the angle between aortic valve annulus plane and horizontal
                  plane/vertebra) exceeds 70° (in the case of left subclavian artery) and 30° (in
                  the case of right subclavian artery).

               -  Vessel diameter of subclavian artery is less than 6 mm.

               -  Transarterial access not able to accommodate an 18Fr sheath.

         32. Direct Aortic Artery as third line choice of access. Patients are excluded from Direct
             Aortic access if:

               -  Access site is less than 6 cm from the aortic valve basal plane

               -  Access site has calcification or porcelain aorta

               -  Access site and delivery trajectory contain RIMA or patent RIMA graft
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shonan Kamakura General Hospital</name>
      <address>
        <city>Kamakura</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cerebral and Cardiovascular Center</name>
      <address>
        <city>Suita-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita-Shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Medical University</name>
      <address>
        <city>Hidaka-shi</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2012</study_first_submitted>
  <study_first_submitted_qc>July 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2012</study_first_posted>
  <last_update_submitted>October 29, 2015</last_update_submitted>
  <last_update_submitted_qc>October 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Valvular Heart Disease</keyword>
  <keyword>Severe Aortic Stenosis</keyword>
  <keyword>Aortic Valve Replacement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>April 27, 2016</submitted>
    <returned>June 3, 2016</returned>
    <submitted>October 28, 2016</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>November 15, 2016</submitted>
    <returned>January 11, 2017</returned>
    <submitted>February 8, 2017</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>March 21, 2017</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>April 5, 2017</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>May 19, 2017</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>October 25, 2017</submitted>
    <submission_canceled>Unknown</submission_canceled>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

